Showing results (621-630 of 2,811) with videos related to
Sort By:
Pageof 282
Expert Opinion on Drug Safety|October 2, 2024
Adverse events associated with azithromycin and clarithromycin in adults aged ≥65: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) databaseZhenpo Zhang, Jiaxin He, Yankun Liang, et al.Expert Opinion on Drug Safety|October 2, 2024
Adverse events in patients with cardiovascular disease taking proton pump inhibitorsAitor Lanas-Gimeno, Ángel LanasExpert Opinion on Drug Safety|October 16, 2024
Adverse reaction of specific acute kidney injury caused by atorvastatin: an actual study based on the database of the US FDA adverse event reporting systemDongqiang Luo, Manting Liu, Zhenye Chen, et al.Expert Opinion on Drug Safety|October 16, 2024
Neurotoxicity associated with chimeric antigen receptor T-cell therapy: a real-world study leveraging the FDA Adverse Event Reporting SystemYinghong Zhai, Lei Yuan, Shihua Fang, et al.Expert Opinion on Drug Safety|October 16, 2024
Thromboembolism adverse event profiles of thrombopoietin receptor agonists: a real-world, pharmacovigilance studyXintian Xu, Lingxiao Zhang, Xiaoyu Zhang, et al.Expert Opinion on Drug Safety|October 11, 2024
Combined nephrotoxicity of Polymyxins and Vancomycin: a study on adverse event reporting for monotherapy versus combinations using the FDA adverse event reporting system (FAERS)Ruijia Zhan, Jiageng Lin, Miao Dai, et al.Expert Opinion on Drug Safety|October 10, 2024
Real-world pharmacovigilance study of FDA adverse event reporting system events for finerenoneYouqi Huang, Hongjin Gao, Yuze Lin, et al.Expert Opinion on Drug Safety|October 11, 2024
Nonsteroidal anti-inflammatory drugs-associated vanishing bile duct syndrome: a real-world retrospective and disproportionality analysisJianglin Wang, Cuifang Wu, Zhenzhen DengExpert Opinion on Drug Safety|October 4, 2024
Safety considerations for drugs newly approved for treating acute myeloid leukemiaAleksandra Gołos, Joanna Góra-Tybor, Tadeusz RobakExpert Opinion on Drug Safety|August 19, 2024
Safety profiles of tetracycline-class drugs: a pharmacovigilance analysis of the FAERS databaseXu Zhang, Juan Pan, Xiaojuan Zhang, et al.Pageof 282